Search

Displaying results 6271 - 6280 of 10000 in total
  1. Drug

    Tovecimig

    go.drugbank.com/drugs/DB30220
    Investigational

    NOV1501 is a biologic drug. … Phase 2 Study Dose of ABL001).

    Categories: Heterocyclic Compounds, 1-Ring
  2. Drug

    Lutetium (177Lu) NeoB

    go.drugbank.com/drugs/DB30389
    Investigational

    Lutetium (177Lu) NeoB is a biologic drug.

  3. Drug

    ARI-0001

    go.drugbank.com/drugs/DB30635
    Investigational

    ARI-0001 is a biologic drug. ARI-0001 is under investigation in clinical trial NCT05641428 (Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL).

  4. Drug

    Triplizumab

    go.drugbank.com/drugs/DB30669
    Investigational

    triplizumab is a biologic drug. triplizumab is under investigation in clinical trial NCT06486220 (PFLL Combined With PD-1 Antibody With or Without FMT for Oligometastatic NPC,a Phase III ,Open, Randomized

  5. Drug

    FRAX1036

    go.drugbank.com/drugs/DB31834
    Experimental

    FRAX1036 is a p21-activated kinase (PAK) inhibitor.

  6. Drug

    MF-300

    go.drugbank.com/drugs/DB32060
    Investigational

    As a potential candidate for the treatment of sarcopenia, it has undergone phase 1 studies to evaluate safety, tolerability, and PK/PD characteristics.[A275368,L54983]

  7. Drug

    SCY-247

    go.drugbank.com/drugs/DB32724
    Experimental

    SCY-247 is a second generation triterpenoid.

  8. Drug

    GLB-004

    go.drugbank.com/drugs/DB32796
    Experimental

    GLB-004 is a molecular glue degrader targeting ARNT(HIF-1β).[L56125, L56126]

  9. Drug

    GLB-005

    go.drugbank.com/drugs/DB32797
    Experimental

    GLB-005 is a molecular glue degrader targeting WIZ and is being investigated for treatment of sickle cell disease and β-thalassemia.[L56125, L56126, L56128]

  10. Drug

    GLB-007

    go.drugbank.com/drugs/DB32798
    Experimental

    GLB-007 is a molecular glue degrader targeting WIZ and ZBTB7A.[L56125, L56126, L56128]